良性前列腺增生的病理生理学：该疾病药物治疗的见解
Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.
作者信息
Lepor Herbert
机构信息
Department of Urology, New York University School of Medicine New York, NY.
出版信息
Rev Urol. 2009 Fall;11(Suppl 1):S9-S13.
Abstract
The medical treatment of benign prostatic hyperplasia (BPH) has its roots in the early 1970s. During this era, the first clinical trials investigating alpha-blockade and androgen deprivation therapy were reported for men with clinical BPH. The observation that clinical BPH was improved following administration of both alpha-blockers and androgen deprivation therapy supported the evolving paradigm that clinical BPH resulted from dynamic and static pathways. During the past several decades, the evolution of alpha-blockers for the treatment of BPH has been impacted by innovations targeted to simplify the administration and improve tolerability while maintaining their effectiveness.
摘要
良性前列腺增生（BPH）的医学治疗始于20世纪70年代初。在这个时期，首次报道了针对临床BPH男性的α受体阻滞剂和雄激素剥夺疗法的临床试验。服用α受体阻滞剂和雄激素剥夺疗法后临床BPH得到改善这一观察结果支持了不断发展的范式，即临床BPH是由动态和静态途径导致的。在过去几十年中，用于治疗BPH的α受体阻滞剂的发展受到了旨在简化给药并提高耐受性同时保持其有效性的创新的影响。
相似文献
1
Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.
Rev Urol. 2009 Fall;11(Suppl 1):S9-S13.
2
Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
Urol Clin North Am. 2016 Aug;43(3):311-23. doi: 10.1016/j.ucl.2016.04.009.
3
Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. doi: 10.1016/s1543-5946(05)00031-0.
4
The role of combination medical therapy in benign prostatic hyperplasia.
Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51.
5
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007.
6
Early treatment of benign prostatic hyperplasia: implications for reducing the risk of permanent bladder damage.
Drugs Aging. 2003;20(3):185-95. doi: 10.2165/00002512-200320030-00003.
7
Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.
Prostate Suppl. 1990;3:75-84. doi: 10.1002/pros.2990170508.
8
Benign prostatic hyperplasia - progress in pathophysiology and management.
Pol Merkur Lekarski. 2015 Nov;39(233):263-70.
9
Emerging drugs for the treatment of benign prostatic hyperplasia.
Expert Opin Emerg Drugs. 2017 Sep;22(3):201-212. doi: 10.1080/14728214.2017.1369953. Epub 2017 Aug 30.
10
[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Prog Urol. 2015 Jun;25(7):404-12. doi: 10.1016/j.purol.2015.02.008. Epub 2015 Apr 2.
引用本文的文献
1
Prostatic Artery Embolization: Technical Pearls.
Semin Intervent Radiol. 2022 Dec 20;39(6):555-561. doi: 10.1055/s-0042-1759690. eCollection 2022 Dec.
2
Fall risk related to subtype-specific alpha-antagonists for benign prostatic hyperplasia: a nationwide Korean population-based cohort study.
World J Urol. 2022 Dec;40(12):3043-3048. doi: 10.1007/s00345-022-04195-w. Epub 2022 Oct 31.
3
Comprehensive Review on Current Controversies and Debate in Prostate Artery Embolization.
Turk J Urol. 2022 May;48(3):166-173. doi: 10.5152/tud.2022.21337.
4
Increased risk of subsequent benign prostatic hyperplasia in non-Helicobacter pylori-infected peptic ulcer patients: a population-based cohort study.
Sci Rep. 2020 Dec 10;10(1):21719. doi: 10.1038/s41598-020-78913-y.
5
The Relationships between Thyroid Hormone Levels and Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.
World J Mens Health. 2019 Sep;37(3):364-371. doi: 10.5534/wjmh.180084. Epub 2019 Jan 4.
6
α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
Adv Ther. 2017 Jan;33(12):2110-2121. doi: 10.1007/s12325-016-0423-5. Epub 2016 Oct 17.
7
Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.
Drugs. 2011 May 7;71(7):897-907. doi: 10.2165/11204780-000000000-00000.
本文引用的文献
1
The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia.
Rev Urol. 2008 Spring;10(2):85-91.
2
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.
Int J Urol. 2008 Mar;15(3):193-9. doi: 10.1111/j.1442-2042.2007.01956.x.
3
The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia.
Rev Urol. 2006;8 Suppl 4(Suppl 4):S3-9.
4
[Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213)].
Yakugaku Zasshi. 2006 Mar;126 Spec no.:209-16. doi: 10.1248/yakushi.126.209.
5
Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia.
J Urol. 2004 Mar;171(3):1029-35. doi: 10.1097/01.ju.0000097026.43866.cc.
6
alpha(1)-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms.
Prostate Cancer Prostatic Dis. 2000 Aug;3(2):76-83. doi: 10.1038/sj.pcan.4500410.
7
Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature.
J Urol. 2000 Aug;164(2):578-83.
8
The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study.
J Urol. 2000 Apr;163(4):1134-7.
9
KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model.
J Pharmacol Exp Ther. 1999 Oct;291(1):81-91.
10
Zotero 插件